Epizyme, Inc. (NASDAQ:EPZM) – Equities research analysts at Jefferies Group lowered their FY2017 earnings per share (EPS) estimates for shares of Epizyme in a research note issued to investors on Thursday. Jefferies Group analyst C. Augustine now anticipates that the biopharmaceutical company will post earnings of ($2.25) per share for the year, down from their previous forecast of ($2.22). Jefferies Group has a “Buy” rating and a $23.00 price objective on the stock. Jefferies Group also issued estimates for Epizyme’s Q4 2017 earnings at ($0.57) EPS, Q1 2018 earnings at ($0.57) EPS, Q2 2018 earnings at ($0.60) EPS, Q3 2018 earnings at ($0.63) EPS, Q4 2018 earnings at ($0.66) EPS, FY2018 earnings at ($2.46) EPS, FY2019 earnings at ($2.51) EPS, FY2020 earnings at ($2.03) EPS and FY2021 earnings at ($0.67) EPS.

Several other equities analysts also recently weighed in on EPZM. Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Wednesday, July 12th. BidaskClub downgraded shares of Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Royal Bank Of Canada set a $20.00 price target on shares of Epizyme and gave the company a “buy” rating in a report on Saturday, August 5th. HC Wainwright reissued a “buy” rating on shares of Epizyme in a report on Monday, August 7th. Finally, Leerink Swann reissued an “outperform” rating and issued a $28.00 target price (down previously from $31.00) on shares of Epizyme in a report on Wednesday, August 9th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $22.67.

ILLEGAL ACTIVITY NOTICE: “Brokers Offer Predictions for Epizyme, Inc.’s FY2017 Earnings (EPZM)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/06/brokers-offer-predictions-for-epizyme-inc-s-fy2017-earnings-epzm.html.

Epizyme (EPZM) opened at $14.20 on Monday.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.02.

In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $16.81, for a total transaction of $252,150.00. Following the sale, the insider now owns 23,123 shares of the company’s stock, valued at $388,697.63. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David M. Mott purchased 200,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were acquired at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the purchase, the director now owns 6,000 shares of the company’s stock, valued at $91,500. The disclosure for this purchase can be found here. Insiders sold 45,000 shares of company stock worth $733,950 in the last three months. Insiders own 25.20% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in EPZM. Palo Alto Investors LLC raised its stake in Epizyme by 18.9% during the second quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock valued at $86,044,000 after purchasing an additional 907,245 shares in the last quarter. State Street Corp raised its stake in Epizyme by 59.6% during the second quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after purchasing an additional 658,727 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in Epizyme during the second quarter valued at $9,726,000. Bain Capital Public Equity Management LLC purchased a new stake in Epizyme during the second quarter valued at $4,331,000. Finally, Vanguard Group Inc. raised its stake in Epizyme by 6.2% during the second quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock valued at $51,640,000 after purchasing an additional 200,982 shares in the last quarter. 72.20% of the stock is currently owned by institutional investors.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.